Elicio Therapeutics Inc. (ELTX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Elicio Therapeutics Inc.

    NASDAQ: ELTX · Real-Time Price · USD
    11.00
    0.15 (1.38%)
    At close: Sep 26, 2025, 3:59 PM
    11.00
    0.00%
    After-hours: Sep 26, 2025, 04:10 PM EDT

    Elicio Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a 28.31M
    Cost of Revenue
    		 1.18M 1.17M 1.06M 1.23M
    Gross Profit
    		 -1.18M -1.17M -1.06M 27.08M
    Operating Income
    		 -44.99M -35.74M -23.73M -25.47M
    Interest Income
    		 777K 373K 64.83K 3.39K
    Pretax Income
    		 -51.9M -35.2M -28.21M -26.4M
    Net Income
    		 -51.9M -35.2M -28.21M -26.4M
    Selling & General & Admin
    		 11.33M 11.9M 5.63M 7.54M
    Research & Development
    		 33.66M 22.68M 18.1M 17.93M
    Other Expenses
    		 -1.18M n/a n/a n/a
    Operating Expenses
    		 43.81M 34.58M 23.73M 25.47M
    Interest Expense
    		 455K 1.06M 3.6M 876.44K
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 44.99M 35.74M 23.73M 25.47M
    Income Tax Expense
    		 n/a n/a n/a 876.44K
    Shares Outstanding (Basic)
    		 12.2M 5.06M 3.1M 3.2M
    Shares Outstanding (Diluted)
    		 12.2M 5.06M 3.1M 3.2M
    EPS (Basic)
    		 -4.25 -6.96 -9.1 -19.32
    EPS (Diluted)
    		 -4.25 -6.96 -9.1 -19.32
    EBITDA
    		 -50.27M -32.97M -23.55M -51.92M
    EBIT
    		 -51.44M -34.14M -24.61M -52.73M
    Depreciation & Amortization
    		 1.18M 1.17M 1.06M 801K

    Add to Watchlist